Petros Pharmaceuticals, Inc.
PTPI
$0.1268
$0.00736.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 725.40K | 1.58M | 1.42M | 1.39M | -364.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 725.40K | 1.58M | 1.42M | 1.39M | -364.30K |
| Cost of Revenue | 264.80K | 287.00K | 329.10K | 331.80K | 158.10K |
| Gross Profit | 460.60K | 1.29M | 1.09M | 1.06M | -522.40K |
| SG&A Expenses | 1.45M | 2.30M | 2.29M | 2.71M | 2.88M |
| Depreciation & Amortization | 656.10K | 739.40K | 717.80K | 717.80K | 802.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.47M | 3.92M | 3.70M | 5.32M | 4.67M |
| Operating Income | -1.75M | -2.34M | -2.28M | -3.93M | -5.04M |
| Income Before Tax | -9.27M | -2.22M | -662.00K | -2.16M | 318.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.27M | -2.22M | -662.00K | -2.16M | 318.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.27M | -2.22M | -662.00K | -2.16M | 318.20K |
| EBIT | -1.75M | -2.34M | -2.28M | -3.93M | -5.04M |
| EBITDA | -1.09M | -1.60M | -1.56M | -3.21M | -4.24M |
| EPS Basic | -26.68 | -13.34 | -9.25 | -42.19 | -40.37 |
| Normalized Basic EPS | -9.75 | -3.53 | -1.40 | -7.10 | 2.09 |
| EPS Diluted | -26.68 | -13.34 | -9.25 | -42.19 | -40.37 |
| Normalized Diluted EPS | -9.75 | -3.53 | -1.40 | -7.10 | 2.09 |
| Average Basic Shares Outstanding | 404.30K | 393.20K | 295.50K | 190.30K | 95.10K |
| Average Diluted Shares Outstanding | 404.30K | 393.20K | 295.50K | 190.30K | 95.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |